Gain Therapeutics (GANX) Non-Current Debt (2020 - 2025)
Historic Non-Current Debt for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $298797.0.
- Gain Therapeutics' Non-Current Debt fell 2056.02% to $298797.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $298797.0, marking a year-over-year decrease of 2056.02%. This contributed to the annual value of $328327.0 for FY2024, which is 2688.46% down from last year.
- As of Q3 2025, Gain Therapeutics' Non-Current Debt stood at $298797.0, which was down 2056.02% from $325359.0 recorded in Q2 2025.
- Gain Therapeutics' 5-year Non-Current Debt high stood at $678255.0 for Q1 2021, and its period low was $298797.0 during Q3 2025.
- Over the past 5 years, Gain Therapeutics' median Non-Current Debt value was $466638.0 (recorded in 2023), while the average stood at $466430.8.
- In the last 5 years, Gain Therapeutics' Non-Current Debt crashed by 932.95% in 2023 and then tumbled by 2688.46% in 2024.
- Quarter analysis of 5 years shows Gain Therapeutics' Non-Current Debt stood at $590468.0 in 2021, then dropped by 16.12% to $495258.0 in 2022, then decreased by 9.33% to $449053.0 in 2023, then dropped by 26.88% to $328327.0 in 2024, then dropped by 8.99% to $298797.0 in 2025.
- Its last three reported values are $298797.0 in Q3 2025, $325359.0 for Q2 2025, and $314476.0 during Q1 2025.